ACC 2026: Tonlamarsen lowers angiotensinogen without extra BP benefit

Pharmaceutical Technology

At the 2026 ACC Scientific Session, the phase II KARDINAL trial tested tonlamarsen in adults with uncontrolled hypertension, comparing single versus monthly dosing on blood pressure and a key biomarke

Clinical DataCardiovascularRead full story